AcelRx aims to get pain tablet in front of ASCs, hospitals after $25M financing

AcelRX Pharmaceuticals closed a $25 million senior secured debt facility, hoping to capitalize on the “high level of interest” its product has garnered from ASCs and other providers.

Advertisement

Three quick details:

1. AcelRx plans to use the senior secured debt facility with Oxford Finance to commercially launch DSUVIA and repay $9 million outstanding under a previous senior credit facility.

2. DSUVIA is a sufentanil sublingual tablet indicated for the management of acute pain severe enough to require an opioid analgesic.

3. AcelRx is hiring hospital account managers to field interest in DSUVIA from hospitals, ASCs and government entities, CEO Vince Angotti said in a press release.

More articles on supply chain:
ASC supply chain tip of the day: Focus on case costing
HCA Healthcare affiliate acquires supply chain management company — 4 insights
3 key opportunities for success in the ASC market

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.